sorafenib has been researched along with Breast Cancer in 84 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (9.52) | 29.6817 |
| 2010's | 60 (71.43) | 24.3611 |
| 2020's | 16 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Fokin, VV; Jo, M; Koizumi, K; Prangsaengtong, O; Priprem, A; Sanphanya, K; Shibahara, N; Vajragupta, O; Wattanapitayakul, SK | 1 |
| Allison, SE; Bourget, K; Chen, YJ; Choucair, H; Dunstan, CR; Koolaji, N; Murray, M; Rawling, T | 1 |
| Al-Tamimi, AS; Angeli, A; Bozdag, M; Bua, S; Carta, F; Ferraroni, M; Kunkler, IH; Langdon, SP; Supuran, CT; Ward, C | 1 |
| Abd El-Meguid, EA; Awad, HM; El Kerdawy, AM; Moustafa, GO; Naglah, AM | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Abdel-Rahman, AA; Alswah, M; El-Adl, K; Omar, AM; Saleh, NM | 1 |
| Guan, XY; Li, GB; Ma, X; Song, C; Wang, HL; Yang, LL; Yu, YM | 1 |
| Abdelhamid, D; Abourehab, MAS; Abuo-Rahma, GEA; Badr, M; Hassan, A; Hassan, HA | 1 |
| Huang, P; Jiang, S; Lin, J; Zhang, Y | 1 |
| Abul Barkat, H; Barkat, MA; Chaurawal, N; Chitkara, D; Jatyan, R; Misra, C; Raza, K; Sharma, T; Singh, B | 1 |
| El-Khouly, OA; El-Messery, SM; El-Sayed, MA; Henen, MA | 1 |
| Augu-Denechere, D; Bonnin, N; Calattini, S; Colomban, O; Fontaine, J; Freyer, G; Guitton, J; Lopez, J; Maillet, D; Payen, L; Peron, J; Puszkiel, A; Schwiertz, V; Tartas, S; Tod, M; Varnier, R; You, B | 1 |
| Chen, S; Feng, R; Hu, Y; Li, J; Li, M; Li, X; Li, Z; Liao, X; Mo, S; Qian, W; Tang, M; Xie, C; Xu, Y; Yu, R; Yuan, S; Zhang, S | 1 |
| Alsfouk, BA; Asmaey, MA; Eissa, IH; Elkady, H; Elkaeed, EB; Husein, DZ; Ibrahim, IM; Metwaly, AM; Yousef, RG | 1 |
| Bai, Y; Dou, J; Feng, F; Liu, F; Liu, W; Luo, R; Sang, M; Zhang, Z | 1 |
| Duan, XC; Feng, ZH; Guo, Y; Li, H; Li, ZY; Liao, A; Liu, M; Wang, GX; Wang, JR; Wang, SM; Xu, MQ; Yin, YF; Zhang, S; Zhang, SQ; Zhang, X | 1 |
| Dattachoudhury, S; Jaganathan, BG; Kumar, A; Sharma, R | 1 |
| Manoharan, R; Natarajan, SR; Ponnusamy, L; Thangaraj, K | 1 |
| Gong, FL; Guo, XL; Li, YS; Wang, L; Yang, XX; Yu, LG; Zhang, XK; Zhao, L | 1 |
| Beal, K; Grkovski, M; Holodny, A; Humm, JL; Jhaveri, KL; Morikawa, A; Patil, S; Schöder, H; Seidman, AD; Tang, K | 1 |
| Amadori, D; Andreis, D; Bravaccini, S; Bronte, G; Cecconetto, L; Donati, C; Farolfi, A; Fedeli, A; Maltoni, R; Rocca, A; Schirone, A; Serra, P | 1 |
| Decker, T; Göhler, T; Indorf, M; Nusch, A; Overkamp, F; Rösel, S; Sahlmann, J; Trarbach, T | 1 |
| Baselga, J; Bergh, J; Bermejo, B; Chan, A; Costa, F; Gómez, HL; Gómez, P; Gradishar, WJ; Huang, L; Hudis, CA; Maeda, P; Mángel, L; Meinhardt, G; Melichar, B; Nagai, SE; Rapoport, BL; Roché, H; Schwartzberg, LS; Zamagni, C; Zhang, J | 1 |
| Han, HK; Kim, HY; Ko, HW; Lee, H; Lee, YJ; Mo, L; Song, JG; Zhao, M | 1 |
| Benavides, R; Bishop, AJR; Chen, Y; Gonçalves, RM; Gorthi, A; Kuhn, J; Loranc, E; Masamsetti, VP; Rajamanickam, S; Reddick, RL; Romero, JC; Tonapi, S; Zanotto-Filho, A | 1 |
| Elmorsy, MA; Gomaa, RM; Mostafa, AS | 1 |
| Dai, J; Dai, X; Geng, F; Li, M; Liu, M | 1 |
| Baek, S; Fasching, P; Foerster, F; Gerber, B; Grischke, EM; Hartmann, S; Klare, P; Marmé, F; Mavratzas, A; Moebus, V; Schmidt, M; Schneeweiss, A; Solomayer, E; Strumberg, D; Windemuth-Kieselbach, C | 1 |
| Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W | 1 |
| Bourget, K; Cui, PH; Gillani, TB; Murray, M; Rawling, T; Wang, XS; Zhou, F | 1 |
| Burkhardt, C; Johnson, C; Miller, KD; Mina, LA; Yu, M; Zon, R | 1 |
| Baselga, J; Costa, F; Gomez, H; Gradishar, WJ; Hudis, CA; Petrenciuc, O; Rapoport, B; Roche, H; Schwartzberg, LS; Shan, M | 1 |
| Greer, PA; Leduc, C; Nagaria, TS; Sangrar, W; Squire, JA; Williams, JL | 1 |
| Chang, KC; Chen, KF; Chu, PY; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, LM | 1 |
| Alfieri, RR; Bonelli, MA; Caffarra, C; Cavazzoni, A; Fumarola, C; Galetti, M; Galvani, E; Generali, D; La Monica, S; Petronini, PG | 1 |
| Chow, W; Chung, C; Frankel, P; Hurria, A; Luu, T; Mortimer, J; Somlo, G | 1 |
| Herrick, WG; Moriarty, T; Nguyen, TV; Peyton, SR; Sleiman, M | 1 |
| Graham, RM; Thompson, JW; Webster, KA | 1 |
| Altun, A; Altun, GG; Babacan, N; Bahceci, A; Kacan, SB; Kacan, T; Sarac, B; Seker, MM | 1 |
| Black, EP; Karabakhtsian, RG; Massarweh, S; Moss, J; Napier, D; Romond, E; Slone, S; Wang, C; Weiss, H | 1 |
| DeWille, J; Hicks, M; Hu, Q; Macrae, E | 1 |
| Lykkesfeldt, AE; Pedersen, AM; Thrane, S; Yde, CW | 1 |
| Aguggini, S; Allevi, G; Andreis, D; Bazzola, L; Berruti, A; Bertoni, R; Bottini, A; Ferrozzi, F; Foroni, C; Fox, SB; Gatter, K; Generali, D; Giardini, R; Harris, AL; Martinotti, M; Milani, M; Petronini, PG; R Cappelletti, M; Reynolds, AR; Strina, C; Turley, H; Venturini, S; Zanoni, V | 1 |
| Almeida, S; Correia, A; Hirvonen, J; Mäkilä, E; Salonen, J; Santos, HA; Shahbazi, MA | 1 |
| Cai, Y; Gao, D; Gao, L; Jia, B; Lai, J; Liu, H; Liu, Z; Wang, F; Zhang, C | 1 |
| Dickson, N; Drosick, D; Earwood, C; Hainsworth, JD; Inhorn, R; Murphy, P; Yardley, DA | 1 |
| Boone, DL; Booth, L; Chuckalovcak, J; Dent, P; Koromilas, AE; McGuire, WP; Poklepovic, A; Roberts, JL; Stringer, DK; Tavallai, M | 1 |
| Amadoz, A; Carbonell-Caballero, J; Crespo, D; Çubuk, C; Dopazo, J; Hidago, MR; Medina, I; Salavert, F | 1 |
| Bennett, LL; Mondal, A | 1 |
| Charamis, H; Esfahani, K; Ferrario, C; Langleben, A; Miller, WH; Nanni, O; Panasci, LC; Scarpi, E; Strepponi, I | 1 |
| Bian, S; Cai, H; Cui, Y; Fan, Y; Liang, J; Sui, J; Sun, Y; Xu, Z; Zhang, X; Zhou, L | 1 |
| Bonhomme-Faivre, L; Cailliez, V; Farinotti, R; Mhiri, A; Noé, G; Paule, B; Saffroy, R; Tandia, M | 1 |
| Kester, M; Robertson, GP; Smith, CD; Tran, MA | 1 |
| Chang, CJ; Chen, YJ; Ding, Q; Hsu, JM; Hung, MC; Huo, L; Kuo, HP; Lai, CC; Lee, DF; Li, LY; Liao, Y; Lin, CY; Tsai, CH; Tsai, FJ; Wei, Y; Xia, W; Yang, JY; Yang, Y; Yen, CJ | 1 |
| Fitch, TR; Flynn, PJ; Hillman, DW; Lingle, WL; Moreno-Aspitia, A; Morton, RF; Perez, EA; Rowland, KM; Wiesenfeld, M | 1 |
| Bergh, J | 1 |
| Hill, KL; Lipson, AC; Sheehan, JM | 1 |
| Bergamini, L; Bianchi, G; Gianni, L; Laferriere, N; Lathia, C; Loibl, S; Peña, C; Raab, G; Salvagni, S; Siena, S; Zamagni, C | 1 |
| Ajani, JA; Cheng, H; Gusani, NJ; Jiang, Y; Kimchi, ET; Staveley-O'Carroll, KF | 1 |
| Alfieri, RR; Belletti, S; Bonelli, MA; Bottini, A; Cavazzoni, A; Dowsett, M; Evans, DB; Fox, SB; Fumarola, C; Galetti, M; Gatti, R; Generali, D; Harris, AL; La Monica, S; Martin, LA; Petronini, PG | 1 |
| Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Ulivi, P; Zoli, W | 1 |
| Moreno-Aspitia, A | 1 |
| Bäuerle, T; Komljenovic, D; Merz, M; Semmler, W; Zwick, S | 1 |
| Chung, GG; Cohen, P; Creswell, K; Eng-Wong, J; Herbolsheimer, P; Isaacs, C; Liu, MC; Novielli, A; Ottaviano, Y; Slack, R; Smith, KL; Warren, R; Wilkinson, M | 1 |
| Andersen, JL; Andersson, M; Kamby, C; Nielsen, DL | 1 |
| Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A | 1 |
| Aglietta, M; Capellero, S; Cavalloni, G; Gammaitoni, L; Giordano, S; Migliardi, G; Milani, A; Moggio, A; Montemurro, F; Pecchioni, C; Peraldo-Neia, C; Petrelli, A; Sapino, A; Valabrega, G; Zaccarello, G | 1 |
| Chang, CJ; Chao, CH; Chen, CT; Hortobagyi, GN; Hsu, JM; Hung, MC; Woodward, WA; Xia, W; Xie, X; Yang, JY | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Kommor, M; Molthrop, DC; Peacock, N; Spigel, DR; Vazquez, ER; Yardley, DA | 1 |
| Gomez, P; Lacouture, ME | 1 |
| Brentani, RR; Cooke, VG; Damascena, A; Duncan, MB; Kalluri, R; Keskin, D; Khan, Z; LeBleu, VS; Maeda, G; O'Connell, JT; Rocha, RM; Sugimoto, H; Teng, Y; Vong, S; Xie, L | 1 |
| Corey, SJ; Park, BJ; Whichard, ZL | 1 |
| Agarwal, S; Elmquist, WF | 1 |
| Baselga, J; Bermejo, B; Ciruelos, EM; Costa, F; de Moraes, AA; Del Giglio, A; Durán, MÁ; Espié, M; Filho, SC; Garicochea, B; Gil Gil, M; Gómez, P; Hoff, PM; Kwon Ro, S; Li, S; Llombart, A; Mathias, C; Morales, J; Ojeda, B; Pinczowski, H; Ribeiro, RA; Roché, H; Segalla, JG; Van Eyll, B | 1 |
| Akli, S; Duong, MT; Hunt, KK; Keyomarsi, K; Liu, W; Lu, Y; Mills, GB; Wei, C; Wingate, HF; Yi, M | 1 |
| Abell, AN; Chen, X; Darr, DB; Duncan, JS; Earp, HS; Frye, SV; Gomez, SM; Granger, DA; Graves, LM; He, X; Hoadley, KA; Jin, J; Johnson, GL; Johnson, NL; Jordan, NV; Kim, WY; Kuan, PF; Major, B; Midland, AA; Nakamura, K; Perou, CM; Sharpless, NE; Smalley, DM; Usary, J; Whittle, MC; Zawistowski, JS; Zhou, B | 1 |
| Gradishar, WJ | 1 |
| Allegood, J; Bareford, MD; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Ogretmen, B; Park, MA; Poklepovic, A; Spiegel, S | 1 |
| Kaklamani, V; Raffin, M; Reddy, S | 1 |
| Bondarde, S; Gradishar, WJ; Jain, M; Kaklamani, V; Lokanatha, D; Lokker, NA; Raina, V; Ro, SK; Sahoo, TP; Schwartzberg, L | 1 |
| Acierno, R; Alberti, S; del Boccio, P; Giannelli, G; Maffia, M; Pieragostino, D; Sacchetta, P; Salzet, M; Simeone, P; Tinelli, A; Toto, C; Vergara, D | 1 |
| Choi, YJ; Heo, K; Lee, JH; Shim, JW; Yang, K | 1 |
| Choi, HN; Hong, SE; Jin, HO; Kim, EK; Kim, HA; Kim, JH; Lee, JK; Noh, WC; Park, IC | 1 |
| Schneider, BP; Sledge, GW | 1 |
10 review(s) available for sorafenib and Breast Cancer
| Article | Year |
|---|---|
Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Topics: Antineoplastic Agents; Benzothiazoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Liver Neoplasms; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
Therapeutic aspects of AMPK in breast cancer: Progress, challenges, and future directions.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Aspirin; Biological Products; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Enzyme Activators; Female; Humans; Metformin; Phosphorylation; Signal Transduction; Sorafenib; Treatment Outcome | 2020 |
Sorafenib for the treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2017 |
Clinical overview of sorafenib in breast cancer.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib | 2010 |
Antiangiogenic therapy for breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Female; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Breast Neoplasms; Cardiotoxins; Cardiovascular Diseases; Female; Heart Failure; Humans; Indoles; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk Assessment; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Breast Neoplasms; Female; Hand-Foot Syndrome; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Sorafenib in locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sorafenib; Taxoids; Triazoles | 2012 |
Drug insight: VEGF as a therapeutic target for breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Forecasting; Humans; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A | 2007 |
19 trial(s) available for sorafenib and Breast Cancer
| Article | Year |
|---|---|
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cholangiocarcinoma; Everolimus; Female; Humans; Niacinamide; Phenylurea Compounds; Sorafenib | 2023 |
A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging.
Topics: Brain; Brain Neoplasms; Breast Neoplasms; Female; Humans; Neuroimaging; Positron-Emission Tomography; Sorafenib | 2021 |
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Niacinamide; Paclitaxel; Phenylurea Compounds; Receptor, ErbB-2; Sorafenib; Treatment Outcome | 2017 |
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Diarrhea; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Hypertension; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Receptor, ErbB-2; Sorafenib; Taxoids; Treatment Outcome | 2017 |
Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Double-Blind Method; Drug Administration Schedule; Female; Humans; Middle Aged; Progression-Free Survival; Receptor, ErbB-2; Sorafenib; Treatment Outcome | 2019 |
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Skin Diseases; Sorafenib; Stomatitis; Treatment Outcome | 2013 |
A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |
A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.
Topics: Administration, Oral; Algorithms; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Dosage Calculations; Female; Fluorouracil; Humans; Neoplasm Invasiveness; Niacinamide; Patient Selection; Phenylurea Compounds; Receptor, ErbB-2; Research Design; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Phase I/II trial of vinorelbine and sorafenib in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate; Vinblastine; Vinorelbine | 2014 |
Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Protein Kinase Inhibitors; Receptors, Estrogen; Sorafenib; Tamoxifen; Treatment Outcome | 2014 |
Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epothilones; Female; Humans; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Sorafenib; Treatment Outcome | 2016 |
Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; Female; Humans; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Taxoids | 2009 |
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Breast Neoplasms; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2009 |
New pharmacological developments in the treatment of hepatocellular cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Breast Neoplasms; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Liver Neoplasms; Meta-Analysis as Topic; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Risk Assessment; Severity of Illness Index; Signal Transduction; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzenesulfonates; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Endothelial Cells; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Sorafenib; Stem Cells; Time Factors; Treatment Outcome; Triazoles; United States | 2011 |
A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Pilot Projects; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Brazil; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Sorafenib; Time Factors; Treatment Outcome | 2012 |
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Paclitaxel; Phenylurea Compounds; Receptor, ErbB-2; Sorafenib | 2013 |
55 other study(ies) available for sorafenib and Breast Cancer
| Article | Year |
|---|---|
Synthesis and evaluation of 1-(substituted)-3-prop-2-ynylureas as antiangiogenic agents.
Topics: Angiogenesis Inhibitors; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; HeLa Cells; Humans; Inhibitory Concentration 50; Models, Molecular; Urea | 2012 |
A Novel Arylurea Fatty Acid That Targets the Mitochondrion and Depletes Cardiolipin To Promote Killing of Breast Cancer Cells.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Fatty Acids; Female; Humans; Mice; Mitochondria; Mitochondrial Membranes; Urea; Xenograft Model Antitumor Assays | 2017 |
Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Carbonic Anhydrase Inhibitors; Cell Proliferation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Models, Molecular; Molecular Structure; Sorafenib; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
Design, synthesis, anticancer, and docking of some S- and/or N-heterocyclic derivatives as VEGFR-2 inhibitors.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Chlorocebus aethiops; Doxorubicin; Female; Hep G2 Cells; Heterocyclic Compounds; Humans; Inhibitory Concentration 50; Liver Neoplasms; MCF-7 Cells; Molecular Docking Simulation; Sorafenib; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2; Vero Cells | 2022 |
Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Female; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sirtuin 2; Sorafenib; Synthetic Lethal Mutations; Xenograft Model Antitumor Assays | 2022 |
Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold.
Topics: Adenocarcinoma; Amines; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Sorafenib; Staurosporine; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Antineoplastic Enzyme as Drug Carrier with Activatable Catalytic Activity for Efficient Combined Therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Glucose Oxidase; Humans; Hydrogen Peroxide; Nanoparticles; Neoplasms; Paclitaxel; Sorafenib; Tumor Microenvironment | 2022 |
Oral sorafenib-loaded microemulsion for breast cancer: evidences from the in-vitro evaluations and pharmacokinetic studies.
Topics: Administration, Oral; Biological Availability; Breast Neoplasms; Cell Survival; Drug Carriers; Drug Liberation; Female; Humans; Nanoparticles; Sorafenib | 2022 |
Design, synthesis and computational study of new benzofuran hybrids as dual PI3K/VEGFR2 inhibitors targeting cancer.
Topics: Antineoplastic Agents; Benzofurans; Breast Neoplasms; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Molecular Docking Simulation; Molecular Structure; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Sorafenib; Structure-Activity Relationship; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
SLC27A4-mediated selective uptake of mono-unsaturated fatty acids promotes ferroptosis defense in hepatocellular carcinoma.
Topics: Breast Neoplasms; Carcinoma, Hepatocellular; Fatty Acid Transport Proteins; Fatty Acids; Fatty Acids, Unsaturated; Female; Ferroptosis; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sorafenib; Tumor Microenvironment | 2023 |
Anti-breast cancer potential of a new xanthine derivative: In silico, antiproliferative, selectivity, VEGFR-2 inhibition, apoptosis induction and migration inhibition studies.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Female; Humans; Molecular Docking Simulation; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2023 |
BHQ-Cyanine-Based "Off-On" Long-Circulating Assembly as a Ferroptosis Amplifier for Cancer Treatment: A Lipid-Peroxidation Burst Device.
Topics: Alkanesulfonates; Animals; Azo Compounds; Breast Neoplasms; Female; Ferroptosis; Humans; Lipid Peroxidation; Magnetite Nanoparticles; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Rats; Rats, Sprague-Dawley; Sorafenib; Xenograft Model Antitumor Assays | 2019 |
Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid.
Topics: 20-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Dinoprostone; Female; Flufenamic Acid; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Nanostructures; Silicon Dioxide; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
Sorafenib Inhibits Proliferation, Migration and Invasion of Breast Cancer Cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Movement; Cell Proliferation; Cell Survival; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; MCF-7 Cells; Mitochondria; Neoplasm Invasiveness; Sorafenib; Superoxides | 2020 |
Galectin-3 expression and secretion by tumor-associated macrophages in hypoxia promotes breast cancer progression.
Topics: Adenocarcinoma; Animals; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Clodronic Acid; Coculture Techniques; Disease Progression; Female; Galectin 3; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Lymphatic Metastasis; Macrophages; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Pectins; Signal Transduction; Sorafenib | 2020 |
PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Drug Carriers; Drug Delivery Systems; Female; Hemolysis; Humans; Hyaluronic Acid; Liposomes; Mice; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclophosphamide; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Neovascularization, Pathologic; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Design and synthesis of 2-phenyl benzimidazole derivatives as VEGFR-2 inhibitors with anti-breast cancer activity.
Topics: Benzimidazoles; Binding Sites; Breast Neoplasms; Cell Line; Cell Survival; Doxorubicin; Drug Design; Female; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Sorafenib; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
Rho GTPase Activating Protein 24 (ARHGAP24) Regulates the Anti-Cancer Activity of Sorafenib Against Breast Cancer MDA-MB-231 Cells via the Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathway.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Female; GTPase-Activating Proteins; Humans; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Signal Transduction; Sorafenib; STAT3 Transcription Factor | 2018 |
Anti-proliferative actions of N'-desmethylsorafenib in human breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MAP Kinase Signaling System; MCF-7 Cells; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinases; Drug Synergism; ErbB Receptors; Female; Flavonoids; Humans; Lung Neoplasms; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Knockout; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; raf Kinases; ras Proteins; Receptor, ErbB-2; Sorafenib; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Female; Gene Expression; Humans; Immunohistochemistry; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-raf; Sorafenib; STAT3 Transcription Factor | 2013 |
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Anilides; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; Down-Regulation; Energy Metabolism; Female; Glucose; Glucose Transporter Type 1; Glycolysis; Humans; Inhibitory Concentration 50; Mechanistic Target of Rapamycin Complex 1; Mitochondria; Multiprotein Complexes; Neoplasm Proteins; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; RNA, Small Interfering; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2013 |
Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening.
Topics: Antineoplastic Agents; Biomechanical Phenomena; Breast; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Collagen; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2014 |
Inhibition of the vacuolar ATPase induces Bnip3-dependent death of cancer cells and a reduction in tumor burden and metastasis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Butadienes; Cell Hypoxia; Enzyme Inhibitors; Gene Knockdown Techniques; Heterografts; Humans; Hydrogen-Ion Concentration; Macrolides; MAP Kinase Signaling System; MCF-7 Cells; Membrane Proteins; Mice; Neoplasm Metastasis; Niacinamide; Nitriles; Phenylurea Compounds; Proto-Oncogene Proteins; Sorafenib; Tumor Burden; Vacuolar Proton-Translocating ATPases | 2014 |
Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Female; Humans; Lapatinib; MCF-7 Cells; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Vascular Endothelial Growth Factor A | 2014 |
JUNB promotes the survival of Flavopiridol treated human breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Sorafenib; Transcription Factors; Treatment Outcome | 2014 |
Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α.
Topics: Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 3-alpha; Humans; MCF-7 Cells; Niacinamide; Nuclear Receptor Coactivator 3; Phenylurea Compounds; Pyrimidines; Sorafenib; Tamoxifen | 2014 |
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer.
Topics: Administration, Metronomic; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Female; Humans; Letrozole; Middle Aged; Niacinamide; Nitriles; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Triazoles | 2015 |
Cyclodextrin-Modified Porous Silicon Nanoparticles for Efficient Sustained Drug Delivery and Proliferation Inhibition of Breast Cancer Cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclodextrins; Drug Delivery Systems; Drug Liberation; Female; Flow Cytometry; Humans; Kidney; Liver; Nanoparticles; Niacinamide; Particle Size; Phenylurea Compounds; Porosity; Rats; Silicon; Sorafenib; Spectroscopy, Fourier Transform Infrared | 2015 |
Inhibition of tumor growth and metastasis by photoimmunotherapy targeting tumor-associated macrophage in a sorafenib-resistant tumor model.
Topics: Animals; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Immunotherapy; Macrophages; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Phototherapy; RAW 264.7 Cells; Sorafenib | 2016 |
[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; NF-kappa B; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Actionable pathways: interactive discovery of therapeutic targets using signaling pathway models.
Topics: Antineoplastic Agents; Breast Neoplasms; Computer Graphics; Computer Simulation; Drug Discovery; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Information Storage and Retrieval; Internet; Metabolic Networks and Pathways; Models, Statistical; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Signal Transduction; Software; Sorafenib | 2016 |
Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caspase 3; Cell Cycle Checkpoints; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Humans; MCF-7 Cells; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Resveratrol; Sorafenib; Stilbenes; Treatment Outcome | 2016 |
Synergistic chemotherapeutic effect of sorafenib-loaded pullulan-Dox conjugate nanoparticles against murine breast carcinoma.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Female; Glucans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Carcinoma, Hepatocellular; DNA; Drug Monitoring; Female; Genotype; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2017 |
Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Ceramides; Drug Synergism; Humans; Liposomes; Melanoma; Mitogen-Activated Protein Kinases; Nanoparticles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib | 2008 |
Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Humans; MAP Kinase Signaling System; Mutagenesis, Site-Directed; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; NIMA-Interacting Peptidylprolyl Isomerase; Peptidylprolyl Isomerase; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib | 2008 |
Quo vadis with targeted drugs in the 21st century?
Topics: Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; ErbB Receptors; Female; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Sorafenib | 2009 |
Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Brain; Brain Edema; Brain Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Seizures; Sorafenib; Sunitinib | 2009 |
Synergistic activity of letrozole and sorafenib on breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Inducing Factor; Aromatase; Aromatase Inhibitors; Benzenesulfonates; Breast Neoplasms; Caspase 7; Caspase 9; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cytochromes c; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Female; Humans; Letrozole; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Niacinamide; Nitriles; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-myc; Pyridines; Retinoblastoma Protein; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Testosterone; Time Factors; TOR Serine-Threonine Kinases; Transfection; Triazoles | 2010 |
Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzenesulfonates; Breast Neoplasms; Calcium; Cell Division; Cell Line, Tumor; Cytosol; DNA Primers; Endoplasmic Reticulum; Flow Cytometry; Gefitinib; Humans; Lapatinib; Membrane Potentials; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib | 2010 |
Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Female; Humans; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Rats; Rats, Nude; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Sorafenib; Survivin; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.
Topics: Animals; Benzenesulfonates; Benzimidazoles; beta Catenin; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Centrosome; Chromosome Aberrations; DNA Breaks, Double-Stranded; DNA Damage; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Models, Biological; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Polycomb Repressive Complex 2; Proto-Oncogene Proteins c-raf; Pyridines; Rad51 Recombinase; Signal Transduction; Sorafenib; Spheroids, Cellular; Transcription Factors; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2011 |
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Crizotinib; Epithelial-Mesenchymal Transition; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Metastasis; Niacinamide; Pericytes; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Tumor Cells, Cultured | 2012 |
Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Epothilones; Female; Humans; Morpholines; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Pyrimidines; Signal Transduction; Sirolimus; Sorafenib; Tamoxifen; Thiazoles | 2012 |
Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Blood-Brain Barrier; Blotting, Western; Breast Neoplasms; Female; Mice; Mice, Mutant Strains; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.
Topics: Acinar Cells; Animals; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin E; Cyclin-Dependent Kinase 2; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Mammary Glands, Animal; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Isoforms; Proto-Oncogene Proteins B-raf; Purines; Pyridines; Retrospective Studies; Roscovitine; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases | 2012 |
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Breast Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Male; MAP Kinase Kinase 1; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Proteome; Proto-Oncogene Proteins c-myc; Pyridines; Receptor Protein-Tyrosine Kinases; Sorafenib | 2012 |
Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling.
Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Endosomes; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Gene Knockdown Techniques; Glutamates; Guanine; Humans; MAP Kinase Signaling System; Niacinamide; Pemetrexed; Phenylurea Compounds; Protein Phosphatase 2; Pyridines; Receptor, Platelet-Derived Growth Factor beta; RNA Interference; Sorafenib; src-Family Kinases | 2012 |
Targeting angiogenesis in metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Epithelial Cells; Epithelial-Mesenchymal Transition; Female; Gene Expression; Gene Expression Profiling; Humans; Mesoderm; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperidines; Protein Interaction Maps; Protein Kinases; Proteome; Proteomics; Quinazolines; Sorafenib | 2013 |
The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1α expression.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Chemoradiotherapy; Female; Gene Expression; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Matrix Metalloproteinase 2; MCF-7 Cells; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Sorafenib; Spheroids, Cellular | 2013 |
Inhibition of S6K1 enhances glucose deprivation-induced cell death via downregulation of anti-apoptotic proteins in MCF-7 breast cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Down-Regulation; Female; Gene Knockdown Techniques; Glucose; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; MCF-7 Cells; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Survivin; TOR Serine-Threonine Kinases | 2013 |